Q4 2022 Pfizer Inc Earnings Call
Yeah.
Good day, everyone and welcome to Pfizer's fourth quarter 2022 earnings Conference call.
Today's call is being recorded.
At this time I would like to turn the call over to Mr. Chris Stevo Senior Vice President and Chief Investor Relations Officer. Please go ahead Sir.
Thanks Rich.
Welcome to Pfizer's fourth quarter earnings call.
And today by Doctor Albert boiler, our chairman and CEO .
Then our CFO , Dr. Michael Goldstone, Vice President of worldwide research and development in medical.
Joining for the Q&A session. We also have asphalt Bong chief commercial officer, and President of Global Biopharmaceutical symptoms Mirror Malik our chief business Innovation Officer, Dr. William Powell, our Chief Development Officer.
Linked quarter, our general counsel.
Before we begin the call I want to remind you of some logistical items.
The materials for this call and other earnings related materials on the Investor Relations section of <unk> Dot com.
You see our forward looking statements disclaimer on slide three additional information regarding these statements and our non-GAAP financial measures is available in our earnings release as well as in our SEC forms 10-K, and 10-Q under risk factors and forward looking information and factors that may affect future results.
Forward looking statements on the call are subject to substantial risks and uncertainties.
The only cause original date, and we undertake no obligation to update or revise any of the statements with that I will turn the call over to Albert. Thank you, Chris Good morning, everyone and thank you for joining us today.
During this morning's call.
Almost all high large firms.
And share some thoughts regarding farthest exciting near and long term growth.
Revenue during the quarter our spending.
Spending year for Pfizer on multiple fronts.
We exceeded Congress yearly revenues for the first time in our 174 year history.
Maintaining our industry, leading clinical success rates and further improved our cycle times.
We're already went on longer industries.
We were named 10 different best employer base, including those properties going forward to maintain glassdoor and others and most importantly, more than one 3 billion.
Female patients around the world, we're <unk> with our medicines and vaccines.
Humbling consumer.
Our key growth drivers for the full year 2022, including global sales of <unk>.
Growth of collateral being developed markets.
Launch of railroad before we adopt population in the U S. The continued strong growth Eric was Goldman.
The strength of our Green Dot family globally.
<unk> newly acquired North Dakota.
Right.
Great.
Yeah.
Looking at tax reform.
The strong operational growth.
Two 9% in 2023.
Excluding revenue from our COVID-19 programs.
The impact of foreign exchange.
We expect our potential new launches newly acquired brokerage underlying progress with all we're all contribute to this growth.
These projections include our forecast for several important professional programs lunches, including our RSV F vaccine for older adults.
Zero primary PBR.
Third indication.
And brokerage and cognizant came to us through recent business development activities, including its roster of books for Lucerne.
It is not there.
Hmm.
Migraine and breakdown for sickle cell disease.
We are in the midst.
18 months period during which we expect to have up to an unprecedented 90, new products or indications in Denmark.
Steve this might be offering our internal pipeline.
The remaining four coming to Pfizer because just explained.
A recent business development deals.
Recognizing the importance of these potential launches.
It is also expected in 2020 before both Pfizer and the patients who rely on our innovation.
We are increasing the support we are putting behind them by investing an incremental $1 3 billion in 2023.
Dave will provide more details can be some investments during the presentation.
One example of a product breadth is already benefiting from this additional support.
So big.
With the recently.
And improving growth trajectory, but we expect to continue through the course of 'twenty three.
In the fourth quarter of 2022.
<unk> new to brand prescriptions.
84% sequentially.
The fastest growth rate in the crush.
We have started 2023 with 65% commercial formulary access.
And do you expect the axis to continued to improve during the year, especially with the upcoming expected expansion of the U S indication during adolescence.
Are there lessons, so hope to repeat year schools.
These properties.
We also introduced a new direct to consumer campaign in November which increased patient awareness of speaker.
More patients asking their doctors.
We look forward to the expected U S losses over thrust in ulcerative colitis.
We're simply in our PCR reactor.
As well as the expected launch of <unk>.
Biosimilar to Humira to further expand our franchise.
This year.
However, we recognize investors are not very interesting to hear of this year's guidance.
Also to understand the long term growth prospects of the company.
Our questions are focused on our plans to offset the expected 17 billion in park or the employees between 20 to 25 in 2017.
And our own corporate fixtures for our COVID-19 products.
We will try to address both starting with the slide regarding our business excluding coffee.
As you can see we start we expect this is Steve over 19 potential launches that are coming from already terminal pipeline.
<unk> generated 20, DRP revenues that were more than offset the expected and Louis lawsuits forecast for 2005.
Thank you Sir.
The potential $20 billion in destock these areas capacity.
I would also point out that some of the potential launches are expected to be bigger contributors or grow than ours.
And all 15 work to achieve their full potential.
Figure could go even higher.
In addition, we believe we have the ability if successful.
At least 25 billion of risk adjusted revenues through our <unk> top line expectations.
Business development activities.
As we have said previously we believe the deals we have already done so.
<unk>.
Global blood therapeutics.
Wireless revenue.
However, the potential gives us more than 40% of the wave there was approximately $10 5 billion in expected 'twenty therapy right.
I am very pleased to see.
The omnibus consensus expectations.
The same revenues.
Already reached $9 5 billion.
Closing materially the golf, but previously existed between internal and external expectations.
For these products.
The launch or are expected to launch subject to regulatory approval in 2023.
We also have more than enough capital to invest in the addition of opportunities as needed to meet or exceed destock.
First.
We have many more potential vaccines and medicines in our pipeline with numerous launches expected in the 24 to 2030 timeframe.
Yes from a clinical trial is underway.
Some of the most promising assets include our oral <unk> cognizant for diabetes and obesity all of them are under these tuck ins.
Thanks.
Sure.
Potential vaccines for Lyme disease singles.
Mountable Euro cordless product candidates, including higher before serving women, our CDK inhibitor, so our endocrine receptor positive breast cancer.
Our gene therapy currently there's sort of a premium a b.
B <unk> muscular dystrophy.
Finally, our A&P antibody treatment and many more.
If approved we expect each of these to be incremental contributors to our growth aspirations sort of 25 and beyond.
Even without any additional potential brokers, we expect October five brachytherapy revenue CAGR to be approximately 6%.
And some of them are successful the CAGR.
<unk>.
Now, let me turn my attention to our COVID-19 portfolio.
At the Jpmorgan conference earlier this month I spoke about expecting 2023 to be a transition year, representing a low point for in October through a determination.
Let me provide a little more.
A bit more color.
I will start with the U S. As an example.
In 2020% to 31% over the population.
<unk> hundred 40 million Americans receive an average one four doses of COVID-19 vaccines for a total of $144 million.
For Americas, there was 64% or 92 over these positive 44 million doses as you can see the first of all.
In 'twenty to 'twenty, three we expect about 24% over the population or 79 people to receive vaccine doses for COVID-19 during this year.
This drop is due to expected sure.
Private approximations.
Reduced compliance with recommendations.
We expect they will receive about 1.3 doses, but pressure on average through 2023.
The drop is because fewer people that are expected to receive their primary doses and for the most part going into those who are.
Older or higher grades are expected to continue receiving Morgan one booster per year.
This should result in about 102 million total vaccine doses are administered in 'twenty two 'twenty three.
We believe Pfizer would maintain at least 64 markets. There. Therefore expect about 65 million doses or the Pfizer biotech vaccine to be administered in 'twenty directly.
2012, before we expect that utilization rates in markets or figures to stop utilizing come in roughly the same as in 2023.
And starting in 'twenty five.
Continuing in 'twenty and beyond.
We expect to see an increase in public meeting vaccination rates, assuming the successful development and approval of the combination.
Combination product.
The successful introduction of a coffee fruit.
Good over time bring the percentage of Americans receive rate.
COVID-19 vaccine closer to the portion of people getting flu shots, which is currently about 50%.
Outside the U S. We expect these general trends to be similar with some variations from country to country.
So what does this mean for our revenues.
We expect 'twenty to 'twenty three to be a transitional year in the U S. In.
In 2022.
Gold.
Prices.
<unk> doses then eventually use.
These resulted in a government inventory build that we expect to be absorbed some time in 2023, probably the second half of the year.
Around the time.
We expect to start selling <unk>.
Commercial tsakos, our commercial prices.
We expect the in.
In years, 'twenty, 'twenty four and beyond.
The doses and doses used in a year.
More broadly aligned together.
And the commercial progress.
They are relatively stable with falling inflation related price increases.
Now, let me briefly run through Prince Rupert.
In 2022, we estimate the hundred million COVID-19, so dramatic infections.
Fifth in the World excluding China.
Approximately 12% of it.
With approximately 40 million oral therapy costs.
And scrubbing the lager sales there was approximately 90% market share although rates were to stay at the six.
Second half of the year are exceeded the nines.
Keep in mind.
This reflects a four year of reported inflections, but toby the partial year of <unk>.
Its availability due to supply constraints in the first quarter of.
2022.
In 'twenty, three and beyond we expect infections to increased slightly at 2% annually.
Do you waning immune protection over the population.
Starting from reduced vaccination rates.
Similarly, we expect delinquency rates to increase.
Louis Education.
So now all up and Bruce will grow the oral antiviral mark.
All right.
We expect our explorer to maintain very high share despite additional competitive entries.
Given the strong benefit risk profile and brand recognition.
Yeah.
So what does this mean for earnings.
With <unk>, we expect 2023 to be a transitional year for parts of it as well.
In 2022 we sold pandemic prices.
More treatment courses.
Eventually use.
This resulted in a government inventory build but we expect to be absorbed some time in 2023 brokerage second half.
Around the time, we expect to start selling <unk> through the commercial segments commercial price.
We expect in years, 'twenty 'twenty four and beyond.
But the car sold and used will align closely together with them every year.
There has been a great deal of speculation regarding a venue, but uncertain market opportunity for box globally China.
So let me share what.
We have seen.
Yeah.
We have an agreement with one company to import and distribute <unk> in China local company.
And we have a manufacturing agreement with another local Chinese company for local manufacturing.
Pfizer.
Our intentional focus of course is to China in fiscal year 2022.
From December which is the first month of our non U S fiscal year.
Through March we expect to see maybe wheels of courses to meet local demand.
We expect we will be able to sell effectively under government reimbursement through end of March.
Despite China's recent decision not to include exploring other countries nazzaro drug reimbursement Louise we.
We expect to offer their product on the private market. After April 1st unless of course, it leasing opportunity opens up before.
Lastly, I want to point out that while we are expecting increased.
Based on all the regions of the World.
<unk> increase.
We are not including any major non U S sign the contracts in 2023 forecast.
Okay.
Let me close with a few thoughts regarding our scientific games.
R&D continues to be the life block box, you will see us as a company, which is why we plan to increase our R&D spend by at least eight 7% in 2023 to $12 four.
Pinpoint for rates.
We have a brilliant springs.
In addition to the increased investments.
We are taking steps not told me to further improve our industry, leading success rates and cycle times, but also to increase overall return on investment in R&D productivity.
As you have seen in the last year, we continuously prioritize our pipeline to focus on the assets that represent potential breakthroughs in terms of potential for et cetera.
Returns, putting more capital behind gloves, Roku TV, just like COPD, one flu or not gone up.
Yeah.
We are attending fiction Park, we are at an inflection point to work from a position of strength with our best in class R&D productivity.
Our pipeline of innovative deposits and one of the highest R&D budgets in the industry.
With that I will turn it over to Dave to provide details on our fourth quarter performance.
And our outlook for 2023 after Dave Michael will provide an update on our R&D pipeline. Thank you Barbara.
Great. Thank you Albert and good morning, everyone. Albert has already taken you through the key drivers of our full year performance. So I will focus my opening remarks on some key highlights from the fourth quarter.
Revenues grew up recently, 13%, primarily driven by strong growth in developed markets. Following the slowdown in deliveries that we discussed in the third quarter.
Ahead of the rollout the piping Easter.
We also saw very strong performance for <unk> outside the U S.
Ongoing launch prep and our 24 adults within the U S.
Excluding direct sales in alliance revenues related to our COVID-19 products Pfizer's revenues grew 5% operationally in the quarter.
And recently acquired products from Bio Haven Pvp are also excluded.
Revenues were up approximately 3% in Q4.
Reported diluted earnings per share this quarter grew 48% to 87.
While adjusted diluted earnings per share of $1 14.
69% on an operational basis in the quarter.
Both EPS figures include a 32% benefit from lower acquired IP R&D expenses compared to last year's fourth quarter.
Once again in the quarter foreign exchange movements significantly impacted our results.
<unk> seen for.
Reducing the fourth quarter revenues by approximately $2 $5 billion or 11%.
And adjusted diluted earnings per share by <unk> 19.
24% compared to FY <unk>.
On a full year basis, foreign exchange negatively impacted revenues by $5 $5 million or 7%.
Adjusted diluted earnings per share by 36 cents or 9%.
Turning now to 2023, and our financial outlook for the company.
Let me first point out that our approach to guidance 2023 is fundamentally different from prior years.
Given the expected transition to commercial markets for our cobot franchise and away from an advanced purchase a cleaner environment. Our guidance reflects our best estimates for both revenues and profits for the products for the full year not just what's been contractually secure.
On a total company basis, we expect revenues of between 67 billion to $71 million, reflecting an operational decline 31% at the midpoint.
Importantly, we expect that revenues from our business, excluding COVID-19 will grow between seven and 9% on an operational basis in 2023.
That growth is projected to be split between contributions from our new product launches R&D recently acquired products as well as our in line portfolio.
The total company revenue declines are entirely driven by our corporate products.
Who should I expect it to go from their peak in 2022 their low point in 'twenty three before potentially returning to growth in 'twenty one.
While patient demand for our Cobra products is expected to remain strong throughout 2023 much of that demand is expected to be fulfilled by products.
We're deliberate to governments in 'twenty, two and recorded as revenues last year.
I want to point out that our total company revenue guidance range is wider than what is implied by the 7% to 9% operational growth rate range for the business excluding COVID-19.
The wider guidance range reflects the potential volatility that we see in our cobot product revenues.
Given that they can be significantly impacted by factors outside of our control.
The infection rates and the severity of the virus as well as the timing for transitioning to a traditional commercial model here in the U S.
And you can see on the slide our cost and expense guidance for 2003.
As I mentioned in my remarks at our Investor event in December .
<unk> and R&D expenses are expected to be significantly higher in 2023 versus 22. Despite the fact that our overall revenues are coming down.
Higher investments in <unk> are significantly focused on the successful launches of the large number of potential new products that Albert highlighted as well as recently acquired assets.
Additionally, the expected commercial launch of both commodity impacts globally in the U S will require additional investments as we transition away from the government market.
Investments are squarely focused on supporting the company's 2025% to 2030 growth aspirations.
We also intend to invest significantly in our research efforts this year.
Multiple exciting and potentially high value programs receiving additional funding.
Including our oral <unk> one programs.
There are a lot of mod and respiratory combination vaccines.
All of this spending to support our commercial and research activities, we believe will not only yield an attractive return.
Also contributing towards setting us on a path to achieving our long term locals.
I point out that when you exclude revenues and expenses related to our Covid products, our expected operating margin profile. This year largely consistent with the prior year.
This reflects incremental investments in <unk> related to launch products.
D as well as lower acquired IP R&D expenses.
In 2023, we are investing in both R&D and SG&A in advance of revenue contribution from new products.
Looking longer term, we expect the spending will be maintained with the piano rolling into this cost base is new product revenues begin to be fully realized with margins improving as a result.
Isn't that 2023, as both a year of investment and transition.
He helped with the outlined many of our key assumptions built into our guidance.
Wanted to walk you through all of the mosquitoes, but both slides 19, and 20 outlines many of the details and.
In summary, these assumptions include strong revenue revenue growth of seven 9% and our business excluding COVID-19.
Additional investments in SG&A, and R&D to support Pfizer's near and longer term growth plans.
Continued patient demand for our COVID-19 related products worldwide.
Vaccination rates declining slightly and utilization of treatment slightly increasing.
We are facing of the European Commission commodity contract over multiple years versus full delivery in 2023.
And finally U S commercialization of coated products in the second half of 2023.
In summary, as we enter a new year, our business is extremely strong with many inline acquired and expected launch products capable of driving strong growth.
With an attractive pipeline of potential products coming in the future.
23 will be an important year for Pfizer and that is why we are deploying our resources into quality execution execution.
Hope, we fully realized the growth opportunities, we see within our portfolio and within our pipeline, which has the potential.
To impact our growth outlook through 2030 and beyond so with that let me turn it over to Mike. Thank.
Thank you Dave today, I want to set the stage for an anticipated catalyst reached 18 months as.
As Albert mentioned, we are in a position of unprecedented strengths in our history and I am excited to share a high level overview of an important strategy for Pfizer R&D to focus our resources on transformative programs, which could be most impactful for patients.
An improved return on R&D investment and create the most value.
We will leverage and continue to innovate our powerhouse capabilities and medicine design and continue to innovate lightspeed drug development to further improve our industry, leading success rates and cycle times.
We have rethought, our approach to rare disease, and we moved from having a standalone research you need to aligning key programs with other therapeutic areas.
We plan to extend that advanced rare disease programs that do not fit into our core therapeutic <unk>.
Our focus at the same time, we plan to tap into the expanding external intervention ecosystem by actively pursued in biotech innovation and imagine innovation that fits strategically and accessing external assets that are differentiated.
Together, we believe these actions will help position us to lead the industry and reach more patients with the most impactful near term blockbuster breakthroughs, while driving for what the next wave of innovations I am pleased to share. Some examples with you today.
We are pursuing potentially transformative efficacy.
Our inflammation and immunology franchise with the potential launches of <unk> and ulcerative colitis.
The Symphony another pizza hut, which both have the potential to be blockbusters.
And our planned phase III study start of MTM to <unk> and time on different sides of this and other idiopathic inflammatory myopathy.
Our next wave of innovation includes two monoclonal antibody candidates for atopic dermatitis, which exemplify our multi specific platform and in house Biomedicine design expertise.
Assets currently in phase one clinical trials each targets three cytokines singing therapeutics, so we refer to them as tri specifics.
On the right our phase one pharmacokinetic profile off the average plasma concentration.
Both molecules that profile suggests that once a month or even less frequent subcutaneous dosing may be supported there is potential for improved efficacy with more potent interleukin four and.
13 utilization plus an expanded breadth of efficacy by blocking thymic stromal doing for pointing to potential to cover more and the types of.
Or by Broking, interleukin 23 to potentially.
Each reduction the phase studies phase one studies continue.
We aim to bolster our third tier experiencing an apology with a strong pipeline that complements our in line portfolio and collectively has blockbuster potential.
We'll talk more about and whatnot them up.
And GBP six one in a moment so will highlight here that we expect multiple data readouts for <unk> was <unk> 62, and how about the logical modeling that these two.
<unk> read outs for collecting them up in sickle cell disease in the second half of 'twenty, four and a phase III readout for my stuff's him up in patients when Hamilton day, you'll be in second quarter of 'twenty three.
<unk> is FDA fast track designation for both hemophilia, a and b with inhibitors, if successful we'd projected submitting for the non inhibitor indication in both a and b hemophilia in the third quarter of 2000 and suites.
We recently announced positive top line results from our Phase III study of our you won't see that begin therapy candidate and expect the pivotal readouts for our hemophilia a gene therapy in the first half of 'twenty before.
We recently presented strong updated phase two data help round out our.
Litigation on.
B cell maturation antigen or <unk>, three targeted bispecific antibodies for relapsed or refractory multiple myeloma in heavily pre treated patients.
Had received at least three classes of prior therapies. These candidates, which has the potential to be a leader in the BC made by specific class demonstrated a high objective response rate of 61% of the patients.
Prior to be somebody targeted treatment.
Deep responses and a manageable safety profile.
Given taxes currently limiting the availability of novel novel therapies, and the Triple class exposed setting.
<unk> has the potential to reach a broader rate the number of patients and so on.
The shelf option with reduced dosing frequency that is administered subcutaneously offering more convenience.
For venous administration.
We'd have a breakthrough therapy designation granted last year, and we're not them up could potentially be approved this year.
After its blockbuster potential patient value beyond the triple class refractory population.
Our clinical strategy aims to move to other lines of therapy.
And combination approaches with the potential if successful for multiple approvals to expand eligibility and duration of therapy.
So our next generation oral once daily hemoglobin S polymerase and polymer essentially named Kevin device.
In a unique class and has the potential to expand the prophylactic treatment of people with sickle cell disease.
Standard of care treatment rates have typically been low due to side effects for efficacy or both.
It looks bright star made substantial progress in preventing hemoglobin polymerization or thinking <unk>.
<unk> six of one as a potentially best in class candidates, which may reduce both hemolysis and frequency of base inclusive crisis.
The most recent data from our phase one multiple ascending dose study showed improvement in that metric and have multiple levels over time.
Hemoglobin occupancy of more than 72% for the 100 milligram maintenance dose and more than 41% for the 150 milligram maintenance dose.
Improvements in Red blood cells, with a higher maintenance doses.
Maintenance doses were well tolerated.
We believe these results may be transformative for patients with a potential to achieve such a 5% to 45% hemoglobin occupancy, which is considered optimal so both hemoglobin oxygen affinity and preventing simply.
And approaches level seen with gene therapy.
This asset is also being studied in an ongoing phase two studies with the seamless phase III redesign we plan to start the phase III part in the second half of 2023.
Next.
We aim to expand our leadership in breast cancer with a pipeline of complementary next wave candidates.
Our CDK <unk> inhibitor that targets improving on CDK four six inhibition standup cap I maximize CDK full coverage. We are studying in a phase one in hormone receptor positive <unk> negative metastatic breast cancer as a single agent and in combination with endocrine therapies.
The majority of hormone receptor positive breast cancers express low CDK six wide CDK four is likely to be a major sales cycle driver.
We have seen that seed care for six inhibition can lead to neutropenia.
It requires more frequent blood tests monitoring, mostly driven by CDK <unk> inhibition and that's complete CDK four inhibition by <unk> inhibitors is challenging due to dose limiting dermatological adverse events.
In the phase one combination study data confirmed objective response rate in combination with the restaurant or let that sort of reached nearly 30%.
And the clinical benefit rate was approximately 50% in 21 patients with measuring things for me.
Sure about disease.
The median progression free survival was more than 24 weeks in 2006 patients, including five without measurable disease.
All patients were heavily pre treated with a median of four lines of prior treatment all patients received prior CDK <unk> inhibitor treatment.
And 67% received prior for Vista.
<unk> was well tolerated with the CDK four dry showing only 15% grade three neutropenia and no grade four do you wish you were scared another patient to achieve partial response and what's on treatment for four to seven weeks. She had received six lines of prior treatments, including <unk>.
Reports six inhibition and for investments.
We are currently engaged in dose optimization and rolling CDK six naive cohort and planning to start a randomized study in second line treatment of estrogen receptor positive <unk> negative metastatic breast cancer this year.
Additional data from our next wave of best Tencent candidate are anticipated in the first half of 'twenty three.
In addition to that since I spoke about today, we anticipate multiple milestones over the next 18 months, we expect the pivotal I brands readout.
Or more receptive positive or <unk> positive metastatic breast cancer.
Pivotal study starts.
471, and a phase two readout for our <unk> inhibitor.
We have achieved credible advancement in our vaccines portfolio.
Losing candidates that harnessed our leadership in mrna with an unprecedented number of milestones expected. In addition to the expected launches shown here, we expect that phase III data readouts from our Mod RNA flu candidate vaccine.
And the potential respiratory combination vaccine study start.
Thanks wanted to study of our shingles, Ken denied the first mrna based shingles vaccine program again last week.
And then as I mentioned in immunology as well as internal medicine, he catalysts and potential launches.
Potential blockbusters are planned pivotal study starts minions from beta them up and data readouts in metabolic disease.
We are also making good progress in allowing anti Infectives Brooks O'neil.
Including anticipating full approval ex love it.
And planned studies starts for both our second generation COVID-19, antiviral candidate, which may have no or limited drug drug interaction and our RSV antiviral candidate in closing.
We're optimistic about the managed transformative catalysts emerging from the pipeline.
Pfizer scientists are working with urgency and commitment.
Most patients as quickly as we can thank you, let me turn it over to Chris to start the Q&A session.
Thank you Michael Chelsea why don't you poll for questions. Please.
As many questions as time permits.
Mr Relations will be available after the call.
Is there any detailed questions that youre not able to address on the call itself.
Yes, Sir.
At this time, if you would like to ask a question. Please press star and one keys on your Touchtone phone.
Remove yourself from the queue at any time by pressing star cute.
Once again that is star one to ask a question.
We will take our first question from Louise Chen with Cantor Your line is open.
Thank you for taking my questions here. So first question I had for you is do you expect your Covid flu combo beyond an mrna platform and then I wanted to ask you on RSV vaccine, there's new players in the space and just wondering if you think.
But he could potentially get a preferential recommendation from Asia or is that really hard to achieve.
Last question is on your Tri specific monoclonal antibody is atopic dermatitis still a key focus for you and if so are you moving the focus to this monoclonal antibody or are you still focused arbitrage for atopic dermatitis, often you had an oral PD I'll, probably a topical PDE point I wasn't development. Thank you.
Great.
Do you have in front of the ACI will depend on the data.
It's difficult to say for professor.
We achieved or not.
But for both questions corporate fluids mrna RSV is not.
Micro and then also what about the surprise specific can be partners.
So as Albert spoke about.
Being close expansion we see.
There's room for many opportunities in our atopic dermatitis is we wanted to highlight this as.
Really novel pioneering approach to go beyond the current antibodies in atopic dermatitis with potentially many other allergic diseases, but there is room for several products in our pipeline in both oral and topical segment as we mentioned so this is an area I think we will accept Liam and.
And where the bulk of Kobe.
Hi, Marvin Anthony's readout. It is knock on wood I mean, how do you think.
Well I think if that's your lithium office an opportunity when you have the breadth to have a pipeline with different platform.
We think that the Covid flu, which contains six components and we have made a real good progress in enrolling the study and will start to share data in the near future.
But by itself of course, a fast track forward pending data.
But for the use of a potential triple vaccine.
Rather than adding up more and more mrna with the current technology that we have seen have lead to.
Rick do you initiate the limitation and a natural ability we think this flexibility to add on a pro protein may give you the perfect balance between efficacy and Tolerability fango micro impossible.
We are monitoring multiple technologies in Mexico. So we are using.
Sure.
Fit for purpose skier every time, we feel that by Petrobras as appropriate for the appropriate return to shortly our privates technology fluent corporates. They are speed. These questions. Because there are various other comments. So I'm wondering is ideally positioned to address this.
Thomas we for RSV.
The virus is not changing at all right. So Brooklyn approach occurs.
Bruno.
With the profile.
Hi from a civil war.
When we saw the data.
So well see.
Compared to most people are more difficult to separate with very very high efficacy in our case, our finger its way through.
We've worked with other better procurement multiple.
Approaches in multiple departments.
Sure.
Our next question will come from Karen Flynn with Morgan Stanley . Your line is open.
Great. Thanks for taking the questions maybe two part for me was just wondering if you can provide any more details on the European vaccine European vaccine contracts that were extended just wondering if you were able to secure a higher average price given some of the headlines in the press earlier this week and then latest things.
On tax loaded commercial pricing in the U S. As well was wondering if you could you could weigh in on that and then the second question relates to economics with Bion Tech on a combo vaccine just wondering how that will work in the event that you do go forward with a a combined COVID-19 and seasonal flu message.
Arnie vaccine. Thank you.
I'll take very much one of an answer.
Honestly I think it will be our vaccine <unk>.
As you look at flu vaccine, whether it's developing a biotech horticultural private and economic position in grade and of course, we're extremely pleased.
But we are we are sharing with you.
We are not ready to make any comments regarding the economics.
Okay.
Coffee to improve oxy.
Angela what about the European situation globally for pricing.
So Paul commodity.
In Europe and you know this was a multiyear contract that we entered into Mckesson, Michigan. The member States and so I think the pricing is.
It is what it is for a contract.
Great discussions with the European Commission regarding.
Sweet.
But that doesn't mean it will look like.
Vivek Esport passed I think that was your next question.
You know that is going commercial launch later this year. So we're now preparing western scenarios could look like.
Sure.
Right.
Thank you Arthur and also to.
To repeat I think David mentioned before revenue booked.
In our guidance for this year, we factor when we a portion of the European contracts are with spreads the volumes.
Yes, although no agreement has been reached yet.
Next question please.
Yeah.
Our next question will come from Robyn <unk> with Truest. Your line is open.
Hey, Thanks for taking my question, so just to drill down a little bit on text Bluebird and it looks like a cube numbers are implying about $9 3 million.
Versus say the 12 million that you mentioned for 2022. So I was wondering if you think about the split going forward ex U S could it be somewhat similar do you think it would be more skewed even more even in the U S and ex U S. And then the second question is.
It also could imply that about half of your 20 million contracts were used in 2020. So how do you think about what could it be very minimal revenue as you drill down draw down that pets love It and we'll go into a stockpile.
Thanks.
Sure Andre.
Oh, well, that's part of the U S tax level.
So in 2022 when we launched personal debt.
The first quarter Opex a little bit.
Quota person on.
We did not.
Has sufficient supply because we were still ramping up.
So the total number of doses that were used in the U S. Copaxone is actually less than that.
So that's why you see that.
We used about eight points.
It's one 9 billion.
When actually demand is much more than that.
Then you asked a question about <unk>.
And the difference is you know I can't be it doesn't capture all of the channels that you are talking.
Exact match.
I think that in general for 2023, the number of doses that you will see all of them.
The U S and four.
For ex.
It's just going to be a function.
The contracts that were made the deliveries that we have to make in the country and also the timing of the commercial it looks different in every single country.
Thank you Joseph and also to emphasize that the throat.
Kirk you mentioned higher dropout number not the U S. It's a global number so I believe a very mind, maybe also for activity is approximately in the U S and but I don't know anybody here I'm also an explanation for all kinds of areas. So next question. Please.
Our next.
I'm going to describe that.
I'm sorry for the great because it is a global number excluding time.
Very much.
Our next question will come from Geoff Meacham with Bank of America. Your line is open.
Hey, guys. Good morning, and thanks for the question just.
Just had two the first one is on Covid and when you look at the the 'twenty two 'twenty three demand and beyond really for both products.
I guess I'm trying to better understand the volume side of the equation you guys are baking in the emergence of say, a new variant or maybe a change in behavior.
Towards boosters.
That's the first question. The second one is from a BD perspective.
Do you have a lot of cash and deploy it if your COVID-19 assumptions.
Not quite play out does that inform a number of deals or the size of deals I guess I'm trying to get a view about where BD fits in your AR and your strategic priorities. Thank you.
For our growth.
What is the assumption about the disease, because that's a fundamental assumption behind all this protection.
It is a disease, where continuing for the foreseeable future mine interesting getting hit with the same way, but there are six to nine months. So there would be new patients.
And that.
That would be infections over here and.
So that's the range would be coming down because of a lack of compliance.
We're stopping lives or something to get enough people, but they believe are explanations and basically we are at high risk because they want to make directions.
At the time, but infections, which slide we're growing off because when you have Wayne in your view.
Protection from the population then you will see more infections are actually more severe infection. So these are the assumptions that we're using we're not.
Using assumptions that.
All of the variants we have.
Skipping the protection or their proxy.
We are going into your assumptions.
People will be getting a 1.3 and the beginning had been going down 1.1 0.2 doses.
Prepped for here.
Mr.
What was the second question on the busy yes.
Business development is by far one of our biggest priority is something that I personally take care of and something that we have a very big theme.
Screaming Oh the opportunities so we'd make drugs come here, who is responsible for that area to make some comments about our priorities.
So just specifically to your question as you heard Albert described we set this aspirational goal of 25 billion in 2030 from IBD, where over 40% of the way there was approximately $10 5 billion of that number through the deals that we've done and we feel very confident that we've got the financial flexibility on the balance sheet and the firepower to complete.
What we need to to achieve that goal and we're going to continue to be disciplined about how we pursue that.
Thank you I think we can move to the next question.
Our next question will come from Steve Scala with Cowen Your line is open.
Our alone grew $1 billion in Ela question Vanda quell together added another $1 billion, so with the launch and acquired products growing well what does this guidance imply for the base business in 2023, it seems like a substantial slowdown is implied in the base business in the car.
Yeah.
Second question has Pfizer learned anything from the suppose he our performance to date that would either increase or decrease its confidence in the troughs of mud. Thank you very much.
Okay.
So David you want to say.
Casey the growth.
In line.
New products and acquire broker.
Really good question I think if you look at each one each of those three buckets, we see growth from acquired products, we see acquired.
Our new products and importantly, you see growth in our in line portfolio as well.
Dissipate, nor do we see a slowdown.
I personally really warfare command, Furthermore, fir and I didn't I wasn't about trust.
Alright, I think.
Got it.
Okay.
It's a market that is.
How has he dominated by biologics and then followed by Abbvie attacks you know after the biologics that really.
Earlier treatment.
Yeah.
The earliest eat my position it really hasn't been much innovation, and that's where we see attractive on a fitting in.
Oh pilot Plasmotomy efficacy.
It can be used very well.
He wanted to use them.
Biologic and that's where we see the ability she loves.
Can you segment.
Well because I'm quite excited about the program, we met with Microsoft with something about Yeah. I would just say we're excited about this best in class profile.
The study that we did have a change to redesign we hope and anticipate that we will have no black box warning.
We don't anticipate any required for titration.
<unk> oral dosing, 100% of our patients were in complete remission after a year and we're still right.
Complete remission after one year of steroid free and we also have quick lymphocyte recovery. After discontinuation. So we feel all of these features potentially make I trust him all the best in class.
Exactly the point best in class in the area, but it is poorly served red mountain with card solution. So we see lots of opportunities, but let's go to the next question. Please.
Our next question will come from Colin Bristow with UBS. Your line is open.
Hey, good morning, and thanks for taking the questions.
So, especially okay. They didn't to sort of piggyback on what Jeff was asking and then somebody.
Those slides and comments, you've clearly you're expecting a sort of stable vaccine utilization rate when in the last 12 months. We have seen this number decline on a backdrop of a virus that is evolving to less clinically severe varian can say, yes.
What underpins your confidence in these longer term assumptions.
In terms of you pay the 23 guidance.
You mentioned you'd guided to a sufficient range for variations in infection rate et cetera. I was just wondering how much of an allowance you've made coal the potential timing or reduction in contractual or does that does the current situation with the Brussels negotiation and then maybe just a quick one on the pipeline DMD. This feels noticeably in the background.
But there's other assets at the similar stage.
Just could you update us on your level of enthusiasm and commitment to this program, especially in light of the potential competitor approval in may of this year. Thanks, so much.
<unk> Michael.
We continue to be enthusiastic about gene therapy in DMD.
I think we have actually published the strongest data on the two drugs with efficacy.
Well, there's a lot of biomarkers from our phase one.
So much broad age group than anyone else.
And.
You know I can't comment one, possibly someone else will get the dry and just started about.
We expect data readouts with eon, possibly less than a year and.
We think that.
This could be a very important drug and we will have randomized data, which is not big.
<unk> for the any other application currently to have at that size and scope.
As regards the assumptions, so far probably to protectionism or excuse for example, we are dropping.
So instead of a 31% of people receiving the vaccine, but once the Oxford in 'twenty, two we're going to twenty-four VAT.
I didn't think that level of Oh really people that they are really committed to the idea of getting fractionation center by.
By physicians that they don't need it.
Democracy magazine and the volume of originations. We are also dropping the number of doses. So we'll grow through all three of them have answered it.
As the years progress the number of doses that people are worried a series of small keep in mind, but.
To get the numbers like $1 two during its a very very small percent.
So what you cannot see or something like that maybe 5% of the progression.
A second dose and Ben who will go through these numbers as you will see is a good result.
There's also a primary doses children. So we believe the assumptions are very reasonable.
When these professionals out there covet.
I remain as it is right now.
So nothing more.
More severe.
And nothing but we're making OSB. So do you have to take into consideration but.
Bloggers with Entercom and basically with the counterparty because also because of it.
Can you hear me.
People at the moment.
Of course, the national Grocers.
The convenience or something like that.
And the fact that people are presenting themselves to receive flu vaccines.
But for a combo vaccine would be the same injection and we're of course zero co pay Oh.
Likely wouldnt be carpet choice.
From Congress, so we are quite.
Quite the contrary because somebody some assumptions although of course, they are only assumptions, which we need to wait and see.
The other thing is on the Europe , you asked two questions.
I know that there are almost but I don't think that it is appropriate for us to make any comments why we already have but she has worked with our partners.
We can be strong and we're gonna member states. So we already said that we have talked to are only part of it delivers.
And this year instead of all the delivered.
Grocery or even over to professionals, but we can't make any other comments.
Next question please.
Our next question will come from Hugh Wynne.
With credit Suisse. Your line is open.
Hi, guys morning, it's true when from credit Suisse. Thanks for taking my questions I have a quick clarification on Covid and then my.
My question, So just on the clarification.
And those long term COVID-19 vaccine impacts flights.
Do you expect any U S government sales in 'twenty, four and 'twenty six it just looks like commercial sales from your slides.
So does that mean Medicaid Medicare populations of both add commercial price.
And can you comment on the margin change for the vaccine and packs as you step up to that commercial price.
And secondly, just following on from the base business question from Steve We sold lower revenues ex U S. For some important base business shrunk say allocation was down 19% ex U S Library, it's down minus 22% ex U S. Perhaps in all of that was also a decline there.
You've noted some product product related issues, but are you seeing anything more broadly in the U S, which is making for more difficult environment and going forward should we expect more normal levels ex U S for these products.
A quick one because that's easy we do not expect to him before and 25 and beyond to have government sales in the U S. You talked with things that are most of the movies here other than some small deliveries, which are still pending with the U S government from the ground goes before we won't see in the U S.
Purposes, that's our assumption right now, but we will move into a commercial.
Most of them, but the Macarthur autonomous as with all other boxing some programs.
Moms and changes.
I haven't seen anything yet about performance of our clinical man.
You can calculate we said there is price appropriately at the American then you can make your assumptions for margins, we don't give market. Some specific programs now a little bit on the lower revenue.
Ex U S. I'm, sorry, just want to make any comment from VAT.
Yeah. As you said there was some specific reason for why we saw what we saw for eloquent Ibreath CCD I mean adequate perfectly well.
Yeah, you know the loss of exclusivity in our patent challenges that led to that.
Great.
The U K and Netherlands, I mean, Iran.
From a product and so it goes to set up the reimbursement.
Instead of that the pricing regulation that it typically goes through in Europe , and and I think P. T V.
Yeah.
Is that I think on the T side not on the adult side than on the <unk> side.
Vaccinations I still are not back up to where they are.
Prior to the pandemic. So I think in all three cases, you have a very specific beef and pork.
What you what you saw.
We don't anticipate.
Okay.
We I think instead of thinking.
Sure.
Hey, good mix Christmas British.
Our next question will come from Tim Anderson with Wolfe Research. Your line is open.
Thank you.
I think one of the challenges for you analysts Mauling Pfizer is to try to understand what the flow through to profitability is.
Pax Logan and commodities I'm, hoping directionally you can tell us how that looks going forward. Once you get past this transitional year of 'twenty three 'twenty four and beyond is the profitability of that combined franchise is likely to be higher or less or the same as what it was.
2021 and 2022.
Then.
Second question is.
On SG&A, how much of that increase was driven by inflation in 2023, and just any quick comments on European austerity measures on pricing.
Yeah. So one maybe on the cooling franchise, obviously, we don't give profitability for each product, but you can imagine as we stated before on the vaccine we split our gross margin with a biotech. So therefore that would obviously carry.
More.
Profitability.
Compared to a typical product in tax law, but it's probably the opposite in a sense that we share that the economics of that so that's probably a bit on the larger higher margin side in general.
And the one you can predict for example in the first year of starting to ramp.
Higher R&D expenses.
We maintain our R&D expenses to grow at a very big part of.
Our expenses in 'twenty three is for call. It because you are investing but do you expect over time, though so I guess, if we bring new products.
It will not be as highest Olivia on the contrary.
Prices are going up but first democracy could be prudent but also.
<unk> expense.
Expenses are going up right.
So without wanting to give.
Actually from what it used to be 'twenty, one 'twenty two we expect going forward, we're going to be higher the markets.
All of this equation, we're being three next question. Please.
Our next question will comes from Mohit Bansal with Wells Fargo. Your line is open.
Great. Thanks for taking my question and thanks for all the clarification.
Maybe one question if I can ask.
So regarding the expenses for clothing business as Dave you mentioned that.
You will be essentially Relaunching these progress with the commercial scale and everything so.
So you said it.
So how are you.
So how much costs given that given that your global businesses.
Climbing significantly. This kit are you modeling any kind of cost cuts in that business or shouldnt more dollar basis is that still the same.
Is there any synergies you can achieve so thank you for the vaccine with your existing <unk> business, because the tenants have similar or not in large part is do you think you can you can do more share buybacks given the stock price at this point. Thank you.
Let me take the first two quickly of course as you saw the business is growing up because you'll probably be growing expenses are going up.
Grocery are promoting new launches, including Colgate.
So right now moving into the environment.
And for scrubbing through commercial.
Now with three of them like normal promotion of our products are very fast food and promotions at the beginning of their launch.
So we are growing very hard with promotions to be field forces and all the other educational measures that we're taking when we do these type of launch so that is true.
Clearly these fees.
David are we going to buy back.
Yes.
Yes, really good question I think as we look at our capital allocation at this point in time, we actually see a lot of opportunities.
So our business both from a research perspective, and importantly, getting behind our launches to make sure that we're doing all we can to ensure that our growth trajectory in 'twenty five facilities and those goals and aspirations become reality. So I think our best and highest use of capital right now is investing in our business both internally.
As opposed to competing perspective, I would say never say never to an incremental share repurchase, but that's not that's not high on the priority.
And the market does.
Articles about the sooner scrubber.
Look I've seen it sits right now both in the preschool scrubbed Scarborough by a local physician simply for a very very strong primarily.
Field Force and took a very strong.
Also.
Vaccines grew fazakas covering all these physicians about the auto racks meritor prescribing scrubbed, so clearly a lot of cylinders in retail and in the medical profession.
Let's go to the next caller please.
Our next question will come from Chris Schott with Jpmorgan. Your line is open great.
Great. Thanks, so much for the questions just building on some of the Opex discussion here.
Sure I'm understanding that the Opex dynamics properly over time, so I guess should we think about 'twenty. Two 'twenty three is more of a onetime step up in opex than much slower growth in 'twenty, four and beyond or should we be thinking about this a couple year process as you really get the pipeline and new products ramped in minutes, maybe more second half of the decade before.
We think even about margin bigger margin expansion or is that opex swelling I just wanted to make sure I'm understanding those dynamics properly and then the second one was on the Covid flu a combination I guess is your expectation that the tolerability of that will be similar to what we see with come in already or is there.
Some trade off of we could see maybe slightly higher kind of side effects with the six components you mentioned, but that's offset by the convenience I'm trying to make sure I understand what your expectations are for that but that program. Thanks. So much.
Thank you very much groups to be scientific question two micro first.
Yeah, we think that you know the tolerability will be well known poor with vaccines used in the target population.
And the perceived as toilet bowl and convenient as you describe the combination.
Attract the high volume of flu people to also be able and long short to renew the COVID-19 coverage, particularly with more and more variance coming. So we are very positive I think we are right in the violence of dose and opportunity there.
With that I would say, but obviously the profile of a drug targeting.
We think it's easy to do it too.
Viruses so throughout demos so, let's just go vertical with the efficacy and good tolerability profile.
We believe it will be more challenging but of course it needs to be seen and that's why we believe of ours would be inappropriate and having such a good throbbing prefer offers better coordination Oh for throughput, Vermont, AAA port with MRO mix.
Also there was this question, but I think you touched upon it earlier in your script about how we see going forward expenses of assignment. So importantly, 2023, we're seeing a step up and Thats, a really good investments around the launches and the products that they acquired.
We think are really important to really drive growth in the back half of the decade. So we're very focused on that we do say 23 is probably the peak year of step up from an expenses and then post 'twenty three lease expenses.
After that.
Thank you very much.
Go to the next question.
Our next question will come from David Risinger with SBB Securities. Your line is open.
Yes, thanks, very much and thanks for all of the additional details that you're providing so it seems like the 2023 guidance is conservative.
She is encouraging.
Looking to our packs low bid longer term on slide 11.
I guess I'm surprised that the.
Percentage of symptomatic patients that you expect to be treated with an oral therapy.
Would almost double from 12% to 22% between 22 and 26, even though the pandemic is being viewed as being over.
So I'm, hoping that you could talk a little bit about those assumptions and.
What the denominator is so when you say symptomatic patients.
Is that high risk slash elderly that you're calculating at 12% on go into 'twenty, two et cetera.
And then in terms of the tax law would share.
It was.
Approaching 91% at the year end of 'twenty two according to the slide but only declining to 80% in 2006. When there are several companies both large and small you know ranging from gilead to smaller companies that are planning to develop agents too.
Compete aggressively and you know that could have implications for both volume and pricing longer term so wanted to understand that.
Thank you very much.
David a very good question. So let me try to explain a little bit.
First of all it's not where I was going to 'twenty 317.
Sometimes it's the right the dwell switches in 'twenty two it is a partial year. So it didn't include the full year.
Demand is good.
<unk> 23, or four years 17 and is growing up.
Sofa to Fox, which one it is a small increase in infections and as I explained.
I'm sorry.
The Soviets would be their.
Vaccine rates vaccinations are going down.
So if I wont create.
The way the protection they need professional liquids rich.
Remind me first with a small increase which you Farquhar Murray, 2% based on our modeling and smoked increase both for both the pictures and that's why we also distributed so that's why so the second one is that the more introductions of new Oh for new entrants.
Right well no carbon before 'twenty five 'twenty four 'twenty five in the U S at least.
Well it depends.
Are you able to still be available, which will be fine. If we were being the state of emergency or not.
But if we would not be mistaken for America, which could be like the Chicago bears and.
And we don't see it before I mean with regards to our traditional 25 reduction.
So also as always are increasing.
Overall cross Sir.
Uh huh.
Fox.
It's what also is driving we are dropping markets we are introducing.
Therefore, their rfps are dropping their market share.
Aggressively enough or already let's say very optimistic in therapy.
I'm sorry.
We are the only one right.
Right now 40 years.
Our presence in the market with a label that is.
He is extremely strong with 86% clinical efficacy against horsepower ization and against.
Hi, I'm sort of against that.
Very difficult for everyone wherever you are these days.
Right now.
The studies were run forever likely won't be very long so it's.
Very very difficult for a rig or something like that so as a result, given about four years, we will be.
Uh huh.
Basically they rely on market share plus the excellent profile.
Loyalty, but were being developed all of us are telling us it was very reasonable with our two main thing very high market Saturday because she's in first in class and because you never know.
Concert.
But compared to the second one it felt very it's easy for me, saying so.
70% of the enrollment completion for smartphones.
Next question please.
Our next question will come from Chris <unk> with Goldman Sachs. Your line is open.
Thank you very much two questions one on the tax will bid cross currents there between.
China in terms of the millions of doses that you described for your first fiscal quarter and a potential transition to a private market in China and then you asked for a similar transition will occur to the commercial can you help at all frame. What you think the relative contributions could look like in 'twenty, three and how that could progress and then in particular with regard.
The transition to commercial markets for the Covid.
<unk> products can you share any early color on the discussions or engagement that you are having with payers what kind of dynamics any color there would be helpful, particularly in the broader context, I think global pharmaceutical.
Opportunity with many different therapeutics that will be.
The budget items obesity, Alzheimer's et cetera, so any color on the discussions with parents would be helpful. Thank you.
Right.
Sure.
So I think I'll pass love it.
Again.
Periods of weak.
Can you talk here about till April which is a ram.
In bus market, which gives us access to both public and private channels and then after April .
Okay.
As you heard we have included in our guidance, what we believe we can do.
Most of it yet, but given the fact that the back half of the year.
You know if we can.
Yeah.
It'll be a very dynamic market.
We will continue to make sure that we have supply that will happen.
T lab, just wait and see what happens there.
On the underside of.
U S U S.
I believe we will be transitioning yeah.
We'll have yeah.
Some of the revenue will be made through the completion of a contract that was made with the U S government in 2022.
Yeah.
And then a part of the revenues will come from the commercialization of <unk>.
So youre going to see that play through both of those both of those.
Got it.
I mean, I think you had one more question pay your Scott what is the reaction we've seen.
So it's still early days and especially in the U S side, but that's not happening.
But what I can say is that all.
Had some early discussions already with that agency.
Outside of the U S who have given us.
Early feedback and even if you take a country like the U K.
We have actually had very favorable feedback on the pricing that we provided.
I agree.
Hum.
So I think well you know that.
That's good feedback and I will be taking those learnings and those that don't.
You have a battery of arguments.
Please.
Next question please.
Our next question will come from Carter Gould with Barclays. Your line is open.
Great. Good morning, Thanks for taking the questions and David. Thank you for all the transparency on the underlying assumptions I guess two for me first off just in terms of the upcoming I guess.
Around the end of the public health emergency can you talk about the <unk>.
Potential impact you see on <unk> access as well I'm, specifically thinking about Pac Slovenia populations in this period before we switched to a commercial market, where you're still the government still working through the.
The inventory you have in hand, and then going to the Covid flew a combination just trying to better understand some of your assumptions here.
I guess, when we think about that 26, 40%.
Adoption number some I guess, either the incremental bump from $24 15 per cent or the 40% absolute.
You know just kind of what that implies about how you think the underlying flu market will change I guess, they comply 30% to 80% share within two years, but just wanted to understand kind of the underlying drivers there and how you think about.
That market evolving.
Maybe I try myself quickly because your army go to Starbucks or if there is a kind of Enzo for emergency or we don't think that will have any impact on kind of the rates will have an impact on issuing new shares, but I don't think anything changes in the way of up there.
Industry or not.
So this would be.
Or is that based on these three.
Pretty much.
As regards corporate flu.
Or do you think the reduction of combination for brokers, where it seems if remark yes.
It's amazing the flu market was always a single market from people now and so I'm going to be the chances are for AGA respiratory diseases like Goldman for or honestly when it comes to life.
And I'll step off.
Clear.
We expect that you know are on 24, 25% it is oh accumulation.
Yes.
Believes needs protection and he's been with them enough believes more belief, but their arguments and enough before the invasion of I'm going to get there I don't know a booster for COVID-19 when they present themselves.
Excuse me when the fruit people were presented.
And that would be asked a question maybe one for Lew sing.
Single, our fruit with a combo.
And they will be giving them information.
If I was gonna protecting and even a single injection at the same time zero copay for probably goes well, we believe it's reasonable to expect a 25% stable we'd be comfortably through.
Another 5% of the population and that's what we're talking about were moved closer to a 50% exactly.
People go to them.
So those are the assumptions for Vegas.
Next question please.
Our next question will come from Kerry Holford with their attack your line is open.
Hi folks.
Question comes vaccines case.
Okay.
Can you confirm that.
Keep in mind that second season with Paypal.
It's all in the impassioned discussion in May change my older I know vaccine.
And can you confirm whether U S pouch.
Got it.
Okay.
While you're waiting.
Oh, okay.
And I guess, what you're saying is that.
Right.
We see them you have positive phase III kind of a second.
I could go on for the year is.
It seems like they take us.
Uh huh.
To me that that interesting to me.
<unk> will not need a cold chain.
Okay. Thank you.
Pedro.
Michael.
I mean, we always follow a multi season, our vaccines and we'll share the second season data.
As soon as it's available.
Of course, there are many ways. This can play out with the combination of vaccines.
And.
Cortez into more regular vaccinations Rotterdam protracted.
On.
You also asked about the.
Let's see the flu COVID-19 comparable here.
Both phase III trials, so if we need a full afraid if we have both flu and we expect that you need a phase three that is based on Immunogenicity and safety and not the large loan trying out based on event. So we think we can complete that fast and if anyone can do it.
It's weird so that's very high on our list currently pending data to move with Lightspeed in.
But I think there was a question on reimbursement requirements for Christmas I think yeah, I think Harry you asked the second season for both big data, how that'll impact reimbursement discussions so if we submitted.
I think.
Embark ACP recommendation, but she was once you have basically a pure recommendation or not you are getting or dramatic access for all formulae with move outs copay, so far but I think it won't be the key what they see that people will say Oh, let's go to the next question. Please.
Our next question will come from Andrew Baum with Citi. Your line is open.
Thank you Unpacks louvred following commercial approval and the withdrawal of the EUA, we'll pharmacists prescribing remain intact and then a couple for Michael could you just explain the reasons for the out licensing of the T. L. L. T. L. One a inhibitor really then I apologize if I missed it and then.
In relation to your multi specific antibodies with Tri specifics. This has been tried previously I think abbvie and J&J previously tried in all right and I think in psoriasis with TNF IL seventeens, but they ran into issue with binding affinity and they didn't have efficacy do you think you've managed to solve the issue here.
I don't know if the pharmacist is better I like roofing, but I don't know, we don't have it in our assumptions right now.
Let's go to Michael.
I'll start with Andrew Great question, you touched my heart today.
Have corrected these antibodies that I shot today.
First of all in pharmacokinetics like an excellent single antibody, but suite in one product and to have.
Very high potency, what you asked about actually exceeding the marketed products substantially. So we think it's it's really something that we will move very quickly as we learn more.
And you know you asked about tier one I, we think we have a very good partnership with them that helps us to do more things within our pipeline.
I mean, your Malik earlier.
To that you know we have comments utilization right takes you into Japan. We have you know about half of the value of this product and we have a full on bi specific T. One before that.
That's an.
Active mechanism still around so we think it's such a richness in your space and really enjoy to build ecosystem without doesn't maximize what we bring to patients.
Maybe you want to add something here. The only quick thing I will add injuries. If you. If you look at how prolific our R&D engine has been the total funding demand from all of the R&D programs that were generated would significantly exceed what we guided to as R&D spending in 'twenty to 'twenty three so in that context, we are going to be.
Be very thoughtful about how we prioritize we have a robust process for that and consequently from time to time, you're going to see programs like <unk> that have very clear scientific merit, but we think we're sharing the cost of risk in capabilities with a partner is the best way to create value.
And that's what we did in that situation, we've had a long history of doing that in a number of other situations as well. Thank you and now let's move to the last question.
Our last question will come from FMC Gorman with BMO. Your line is open.
Hi, guys. Thank you for squeezing me in and I'm not going to ask a quick question because I think they were all asked so just looking at business development. When you get bio Haven, what were some of the characteristics of the deal that you want to bring forward and kind of your go forward approach for BD you know how should we think about potential holes in your pipeline that you could fill with external deals. Thank you.
I mean, why don't you take this one sure you know the buyer Haven deal for US represented an excellent opportunity to leverage our capabilities, and specifically where where our capabilities in terms of our global commercial footprint.
I Haven as a company alone could pick out maximize the application of those capabilities can take nanotech and follow on product to places and reaches for patients that they couldn't have gotten too alone and also the way in which we structured that transaction began with an extra that's partnership which we then expanded to take on the full global T jerky.
Franchise and also are excluded some assets that were less relevant to us strategically that created a new call and I think what you can take away from that is that we're going to continue to look for things that are scientific breakthroughs, where we can add capabilities and we're also gonna be creative and disciplined about how we structure our deal and we think that's going to serve as well as we complete our ambition against.
That $25 million.
Thank you Amir.
So in.
In summary, let me close by saying first of all I feel extremely proud.
The team at Pfizer, but was able to deliver a break all records in 'twenty to 'twenty two highest ever revenues harvests are appropriate the highest more importantly, we have a number of patients.
But we protected or treated with our medicines are the best reputation for our company. The most productive wave of R&D with the 18th and 19th products launching the next 18 months.
The R&D machine in terms of multiple measures are all about.
Let's see.
<unk> 22, a clear goal I believe of the bed.
Yeah for Pfizer.
Because we are building on our significant capital position, but we know how to deploy through great growth. We are building on an R&D engine.
More productive than ever in the history of this company and manufacturing.
But it used to be enviable interesting commercial angry at commercial Andrew but it is.
Again, and again and again as the best commercial engine in the industry and of course, the mindset and Pfizer.
But the east characterized but nothing is impossible.
Can make everything possible so without the mine I think that the.
We are moving a car hopefully through even more success from 'twenty to 'twenty three thank you very much for your attention your interest and your support for shareholders right.
Yeah.
Thank you ladies and gentlemen, this does conclude Pfizer's fourth quarter 2022 earnings Conference call. We appreciate your participation and you may disconnect. Your line at any time.
[music].